In short
This article summarizes several clinical trials investigating the use of influenza vaccines containing the A/Victoria/2570/2019 (H1N1)pdm09-like strain. These trials aim to evaluate the safety, immunogenicity, and effectiveness of various influenza vaccine formulations in different populations, including older adults, patients with hematological cancers, and the general adult population. The studies compare high-dose and standard-dose vaccines, as well as different administration methods and combinations with other vaccines.
At a glance
- Vaccine Types
- Quadrivalent inactivated influenza vaccines (QIV), High-dose (HD) and Standard-dose (SD) formulations, mRNA-based candidates, Cell-derived and Egg-derived vaccines
- Study Populations
- Adults aged 50 years and older, Patients with hematological cancers, General adult population
- Primary Objectives
- Evaluate immunogenicity, safety, and effectiveness of vaccines; Compare HD vs SD formulations; Assess co-administration with other vaccines
- Key Outcome Measures
- Antibody responses (HI assay), Seroconversion rates, Geometric mean titers, Clinical outcomes (e.g., hospitalization rates)
- Special Focus Areas
- Older adult populations, Patients with compromised immune systems, Lot-to-lot consistency, Systems biology approaches
What is A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN?
A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215) is a specific strain of the influenza A virus used in the development of flu vaccines. This strain is derived from the H1N1 subtype of influenza A, which was responsible for the 2009 swine flu pandemic. The "PDM09" in its name refers to this pandemic origin.
Influenza viruses are constantly evolving, which is why flu vaccines are updated regularly. This particular strain was isolated in Victoria, Australia in 2019 and has been selected for inclusion in recent flu vaccines due to its representation of currently circulating H1N1 viruses.
Role in Influenza Vaccines
This strain is a key component in many quadrivalent (four-strain) influenza vaccines. It's included to provide protection against H1N1 influenza A viruses that are similar to this strain. Quadrivalent vaccines typically contain:
- Two influenza A strains (including this H1N1 strain)
- Two influenza B strains
The A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN is found in various flu vaccine formulations, including:
- Standard-dose quadrivalent vaccines (like Vaxigrip Tetra and Influvac Tetra)
- High-dose quadrivalent vaccines (like Efluelda)
Clinical Trials and Research
Several clinical trials have been conducted or are ongoing to evaluate vaccines containing this strain:
- A study comparing high-dose and standard-dose quadrivalent influenza vaccines in adults aged 65 and older
- Research on the effectiveness of influenza vaccines in patients with hematological cancers
- Trials evaluating new mRNA-based influenza vaccines that include this strain
These studies aim to assess the immunogenicity (ability to provoke an immune response) and safety of vaccines containing this strain in various populations.
Effectiveness and Immune Response
The effectiveness of vaccines containing the A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN is typically measured by looking at:
- Seroconversion rates: The percentage of people who develop a significant increase in antibodies after vaccination
- Geometric mean titers (GMTs): A measure of the average antibody levels in a group of vaccinated individuals
Clinical trials have shown that vaccines containing this strain can elicit a strong immune response in many individuals. However, the strength of the response can vary based on factors such as age, overall health, and the specific vaccine formulation used.
Safety Profile
Vaccines containing the A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN have generally demonstrated a good safety profile in clinical trials. Common side effects may include:
- Pain, redness, or swelling at the injection site
- Headache
- Fatigue
- Muscle aches
These side effects are typically mild and resolve within a few days. Serious adverse events are rare.
Use in Special Populations
Research has been conducted on the use of vaccines containing this strain in various populations, including:
- Older adults (65 years and above)
- Patients with hematological cancers
- Individuals with chronic medical conditions
These studies aim to ensure that the vaccine is safe and effective in populations that may be at higher risk for influenza complications.
Conclusion
A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215) is an important component of current influenza vaccines, providing protection against circulating H1N1 influenza A viruses. Ongoing research continues to evaluate its effectiveness and safety in various populations and vaccine formulations. As with all influenza vaccines, it's important to receive annual vaccination to ensure protection against the most current strains.